American Heart Journal
Volume 157, Issue 5 , Pages 799-801 , May 2009

Risk assessment in the genomic era: Are we missing the low-hanging fruit?

  • Larry A. Allen, MD, MHS

      Affiliations

    • Division of Cardiology, University of Colorado Denver, Aurora, CO
    • ,
  • Christopher B. Granger, MD

      Affiliations

    • Duke Clinical Research Institute and the Division of Cardiology, Duke University Medical Center, Durham, NC

Received 23 January 2009 ,Accepted 3 February 2009.

References 

  1. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207
  2. Mehta RH. Randomized comparison of early vs delayed invasive strategies in high risk patients with non–ST-segment elevation acute coronary syndromes: main results of the Timing of Intervention in Acute Coronary Syndromes (TIMACS) trial. In: American Heart Association 2008 Scientific Sessions, Late Breaking Clinical Trials Session 2; 2008; New Orleans, LA. 2008;
  3. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  4. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–2870
  5. May HT, Horne BD, Ronnow BS, et al. Superior predictive ability for death of a basic metabolic profile risk score. Am Heart J. 2009;157:946–954
  6. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115:928–935
  7. Pencina MJ, D'Agostino RB, D'Agostino RB, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–172[discussion 207-12]
  8. McGeechan K, Macaskill P, Irwig L, et al. Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. Arch Intern Med. 2008;168:2304–2310
  9. Lloyd-Jones DM, Tian L. Predicting cardiovascular risk: so what do we do now?. Arch Intern Med. 2006;166:1342–1344
  10. Anderson JL, Ronnow BS, Horne BD, et al. Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease. Am J Cardiol. 2007;99:169–174
  11. Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007;50:40–47
  12. Morgan TM, Krumholz HM, Lifton RP, et al. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. Jama. 2007;297:1551–1561
  13. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006;166:1368–1373
  14. Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med. 2009;150:65–72

PII: S0002-8703(09)00127-6

doi: 10.1016/j.ahj.2009.02.003

American Heart Journal
Volume 157, Issue 5 , Pages 799-801 , May 2009

Article Tools